Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1)

Interim data shows triplet therapy with ciforadenant, ipilimumab and nivolumab is feasible and well tolerated; longer follow-up with patients still on therapy needed to determine potential benefit of blocking adenosine signaling

SOUTH SAN FRANCISCO, Calif.,, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that interim data from the Phase 1b/2 clinical trial of ciforadenant for patients with metastatic renal cell cancer (RCC) will be presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2025, which is taking place October 17-21, 2025 in Berlin, Germany. The data will be presented by Katy Beckermann, M.D., Ph.D., Director of Genitourinary Cancer Research at Tennessee Oncology and member of the Kidney Cancer Research Consortium (KCRC), the group that is conducting the trial in collaboration with Corvus.

“We are encouraged by these results exploring ciforadenant in combination with ipilimumab and nivolumab as a potential front-line treatment for renal cell carcinoma,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “Despite enrolling patients with more unfavorable disease compared to historical trials, the triplet combination demonstrated activity that compares favorably to historical results with the doublet alone. These data support our view that blocking adenosine signaling with ciforadenant may provide meaningful benefit for RCC patients. We appreciate the partnership with the Kidney Cancer Research Consortium and we look forward to continuing to follow the 19 patients who remain on therapy to better understand the potential of this approach.”

The open-label Phase 1b/2 clinical trial is evaluating ciforadenant, the Company’s adenosine A2a receptor inhibitor, as a potential first line therapy for metastatic RCC in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). The trial enrolled 50 patients (8 in Phase 1b portion, 42 in Phase 2 portion) with newly diagnosed or recurrent stage IV clear cell RCC that had not received any prior systemic therapy. Patients received ciforadenant 100 mg oral, twice-daily in combination with ipilimumab (anti-CTLA-4) 1mg/kg given once every three weeks for twelve weeks (4 doses) and nivolumab (anti-PD-1) 3mg/kg given once every three weeks.